SAN DIEGO--(BUSINESS WIRE)--Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and ...

SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped ...

Illumina pioneered Next Generation Sequencing (NGS) of DNA, a highly accurate and relatively affordable DNA sequencing technology. As market leader, Illumina quadruple its revenues in 10 years, ...

Illumina (NASDAQ:ILMN) supports global genomic science as nasdaq futures discussions include advanced life sciences platforms ...

Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced the launch of BioInsight, a ...

Illumina, Inc. ILMN recently launched its first product based on its novel Illumina Complete Long Read technology. The high-performance, long-read, human whole-genome sequencing (WGS) assay – Illumina ...

Illumina, Inc. (NASDAQ:ILMN) announced it has signed an agreement with Janssen Research & Development, a unit of Johnson & Johnson (NYSE:JNJ). This collaboration will be the first relating to the ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that it is appointing Susan Tousi as Chief Commercial Officer (CCO), and Dr. Alex Aravanis as Chief Technology Officer (CTO), ...

Dr. Aravanis brings almost 20 years of experience in leading research and development efforts, spanning basic research and technology development through late stage clinical development, and is ...